인쇄하기
취소

Patient alliance concerning about suspension of Olital Tab development, demanding immediate actions

Published: 2018-04-18 18:28:52
Updated: 2018-04-18 18:28:52

As patient advocates expressed concerns about suspension of the Olita Tab development, Hanmi Pharm, the Ministry of Food and Drug Safety(MFDS) and the Ministry of Health and Welfare(MOHW) insisted to prepare follow-up actions as soon as possible.

“Hanmi Pharm submitted a plan to suspend the development and sales of Olita Tab, a targeted therapy for terminal non-small cell lung cancer, to the M...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.